Eurobio Scientific FY26 H1 net income more than doubles to €4.7 million; revenue rises 4.5% to €84.5 million

Bitget2026/09/24 15:40

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eurobio Scientific first-half revenue rose 4.5% to €84.5 million, while operating income climbed 45% to €8.5 million.
Net income more than doubled to €4.7 million; EBITDA increased 20% to €15.8 million.
Gross margin rate edged up 0.2 percentage points to 47.5%, and operating expenses fell to 35.1% of revenue from 37.2%.
Free cash flow totaled €4 million, and net debt stood at €147.4 million, including the EB Development shareholder loan.
CareDx’s Lab Solutions acquisition closed June 30, and EB Development proposed a tender offer at €25.30 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eurobio Scientific SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609241140OMX_____CNEWS_EN_GNW1001274457_en) on September 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Eurobio Scientific FY26 H1 net income more than doubles to €4.7 million; revenue rises 4.5% to €84.5 million

You may also like

Crypto prices